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Effects of Verocytotoxin-1 on Nonadherent Human Monocytes: Binding 
Characteristics, Protein Synthesis, and Induction of Cytokine Release
By Petra A. van Setten, Leo A.H. Monnens, Riet G.G Verstraten, Lambert P.W.J. van den Heuvel,
and Victor W.M. van Hinsbergh
The epidemic form of the hemolytic uremic syndrome (HUS) 
has been associated with a verocytotoxin producing Esche­
richia coli infection. Endothelial cell damage of glomeruli and 
arterioles of the kidney plays a central role in the pathogene­
sis of HUS. A number of observations in vivo and in vitro 
indicate that inflammatory mediators contribute to this pro­
cess. In this study we investigated the binding of 125l-verocy- 
totoxin-1 (VT-1) to freshly isolated human nonadherent 
monocytes as well as the nature of the ligand to which VT- 
1 binds on monocytes. On the average, freshly isolated 
monocytes have 0.07 x 105 specific binding sites for 1Z5I-VT- 
1 per cell. Preincubation of nonadherent monocytes with 
bacterial lipopolysaccharide (LPS) caused a 23- to 30-fold 
increase of specific binding sites for VT-1 as shown by 
Scatchard plot analysis. Thin-layer chromatography of ex­
tracted neutral glycolipids of the cells and subsequent bind­
ing of 125I-VT-1 showed that human monocytes bind VT-1 to 
a globotriaosylceramide (Gb3) species that is different from 
that found on endothelial cells, probably a short-chain fatty
acyl Gb3 or an a-OH-Gb3. In addition, we evaluated the func­
tional consequences of VT-1 binding to human monocytes 
by investigating the effects of VT-1 on the total protein syn­
thesis and, specifically, the production of the cytokines in- 
terleukin-1/3 (IL-1/3), tumor necrosis factor-« (TNF-a), IL-6, 
and IL-8. We observed that VT-1 did not inhibit overall pro­
tein synthesis, nor under basal conditions, neither after stim­
ulation with LPS, in contrast to previous observations with 
endothelial cells. Furthermore, we found that VT-1 induces 
the synthesis of the cytokines IL-1/3, TIMF-a, IL-6, and IL-8 in 
nonstimulated monocytes by a LPS-independent cell activa­
tion. The increase in the production of cytokines was paral­
lelled by an increase in mRNA, as was demonstrated for IL- 
6 by reverse transcription-polymerase chain reaction. These 
data suggest that inflammatory mediators locally produced 
by VT-1-stimulated monocytes may contribute to the 
pathogenic mechanism of the HUS.
© 1996 by The American Society of Hematology.
HE HEMOLYTIC uremic syndrome (HUS) is charac- and cyclooxygenase.14 There is also evidence that endothelial
terized by renal failure, thrombocytopenia, and hemo- cells treated with inflammatory mediators may become more
lytic anemia.1 Infection with a verocytotoxin-1 (VT-1) pro- susceptible to injury. Human umbilical and adult vein endo-
ducing Escherichia coli, mainly 0157H7, has been strongly 
implicated in the etiology of the epidemic form of HUS.2 
Endothelial damage of glomeruli and kidney arterioles has 
a pivotal role in the pathogenesis of HUS. Histopathologic 
studies of the kidney in HUS patients reveal swollen and 
detached endothelial cells, deposits of fibrin, and influx of
thelial cells preincubated with inflammatory mediators TNF- 
OL or interleukin-1 (IL-1) were found to be more sensitive 
for the toxic effect of VT-110 by induction of the glycolipid 
receptor (globotriaosylceramide Gb3) on their surface.11 This 
further favors the suggestion that inflammatory mediators 
may play an important role in the pathogenesis of HUS. In
inflammatory cells, all within the glomerulus.3'5 A number addition to thrombotic thrombocytopenic purpura patients
of observations indicate that inflammatory mediators, in par­
ticular tumor necrosis factor-a (TNF-o:), contribute to this 
pathologic process in HUS.6'11 Endothelial cells respond 
strongly to TNF-a by acquiring new properties, albeit that
who displayed increased plasma concentrations of TNF, IL- 
1/3, and IL-6,15 elevated plasma concentrations of TNF-o;, 
IL-6, and EL-8 have been observed among HUS patients. 
Also, elevated concentrations of TNF-a and IL-6 were found
.  U.-IK
local variation in the response of endothelial cells to TNF- in urine of HUS patients.16,19 For this reason it has been
a  has only been investigated to a limited extent. TNF-a 
induces the expression of various leukocyte adhesion mole-
postulated that locally released cytokines may be involved 
in the development and aggravation of HUS. The culprits of
cules on the endothelial cell surface in vivo and in vitro. It this local release may be monocytes and macrophages, which
reduces the antithrombotic properties of endothelial cells, 
and induces the synthesis of growth factors and cytokines12 
as well as the inducible species of nitric oxide synthase13
upon activation are able to produce and release a number of 
inflammatory mediators including TNF-a and IL-1.20 •e-
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fore, we have investigated if VT-1 itself was able to interact 
with human nonadherent monocytes and to induce the re­
lease of cytokines from these blood cells. While this study 
was being finished, Tesh et al8 reported that mouse peritoneal 
macrophages can be induced to release cytokines after expo­
sure to VT-1. Our report extends this observation to human 
nonadherent monocytes, showing that VT-1 induces the syn­
thesis and release of considerable amounts of TNF-a, IL-1, 
IL-6, and EL-8 by a lipopolysaccharide (LPS)-independent 
cell activation. Furthermore, we demonstrate that human 
nonadherent monocytes contain a VT-1 glycolipid receptor 
that is related to but different from the classical Gb, seen in 
endothelial cells. The number of these receptors is signifi­
cantly enhanced after exposure of monocytes to LPS. VT-1 
interaction with monocytes markedly stimulated cytokine 
production, but, in contrast to other eukaryotic cells with the 
classical Gb3 receptor,21 did not inhibit protein synthesis.
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MATERIALS AND METHODS
Materials. Purified VT-l was kindly provided by Dr M.A. Kar­
mali (Department of Microbiology, The Hospital for Sick Children, 
Toronto, Ontario, Canada) (l.O to l .2 mg protein/niL).22 The endo­
toxin content o f the VT-l preparation was less than 0.05 endotoxin 
units (EU)/mL by Limulus amebocyte lysate assay at detection level 
of 0.05 to 0.10 EU/mL. Percoli was purchased from Pharmacia 
(Uppsala, Sweden). RPMI 1640 Dutch modification supplemented 
with 20 mmol/L HEPES and 6.2 g/L sodium bicarbonate was ob­
tained from Flow Laboratories (Irvine, UK), 1 mmol/L pyruvic acid 
from Sigma (St Louis, MO), 2 mmol/L L-glutamine from G1BCO 
(Grand Island, NY), 40 tng/niL gentamycin from Boehringer Mann­
heim (Mannheim, Germany), and fetal calf serum (FCS), which was 
heat inactivated at 56°C for 30 minutes, was obtained from GIBCO. 
Teflon foil bags were provided by Du Pont de Nemours and Co 
(Geneva, Switzerland). LPS of E coli serotype Ol i i  -B 14 was pur­
chased from GIBCO. 3H-Leu and Nal2,I-iodine were from Amer- 
sham (Amersham, UK) and lodogen iodination from Pierce (Rock­
ford, 1L). The antirat IgM monoclonal against the Gbj receptor was 
a gift from Dr J. Wiels (Institut Gustave Roussy, Villejuif, France).*3 
Cycloheximide and polymyxin B were obtained from Sigma. Chloro­
form, methanol, and hexane were purchased from Merck (Darmstadt, 
Germany). Plastic coated silica gel F 1500 Thin Layer Chromatogra­
phy (TLC) plates were obtained from Schleicherand Schuell (Dassel, 
Germany). Polyisobutylmethacrylate was from Polysciences Inc 
(Washington, MD). A standard mixture of pure neutral glycolipids 
was obtained from Biocarb AB (Lund, Sweden). All other chemicals 
were of analytical grade.
isolation of human monocytes. Mononuclear cells obtained from 
apheresis of healthy male volunteers were immediately diluted in 
ice-cold phosphate-buffered saline (PBS) supplemented with the an­
ticoagulant Na-citrate 2H20 .  Thirty-five milliliters of samples were 
layered on top of 15 mL 1.075 g/mL Percoli and centrifugated for 
30 minutes, 200# at 4°C. Subsequently the interphase was collected 
and washed once. Further purification of the mononuclear cells was 
performed by counterflow centrifugation24 using a CURAME 3000 
elutriator (Dijhstra Vereenigda bv, Lelystad, The Netherlands). 
Monocyte fractions were over 95% pure (as evaluated in cytoeentri- 
fuge preparations after May-Grtinwald-Giesma staining) and viabil­
ity was higher than 96% (as assessed by trypan blue dye exclusion). 
Purified monocytes were cultured immediately.
Culture and stimulation of human monocytes. Previous investi­
gations have shown that monocytes cultured in teflon foil bags are 
not functionally impaired and show minimal activation.25”’'’ For this 
reason all monocytes used for experiments were cultured in teflon 
foil bags. The culture medium consisted of RPMI 1640 Dutch Modi­
fication with 20 mmol/L HEPES, 2 mmol/L L-glutamine, 1 mmol/
L pyruvic acid, 40 gentamycin, and 5% fetal calf serum.
Cells were cultured at a concentration of 3.0 X 10s cells/mL in a 
humidified incubator with 5% CO2 in air at 37"C.
Monocytes were either incubated under basal conditions or stimu­
lated by preincubation with different concentrations of LPS and/ 
or VT-1 for different periods of time. Under basal conditions the 
nonadherent monocytes cultured in teflon foil bags were nonstimu­
lated as was confirmed by their morphology (small rounded cells 
with typical horseshoe-shaped nucleus and a small cytoplasm/nu­
cleus ratio) and low/undetectable cytokine production in the condi­
tioned medium (IL-1/3, IL-6, IL-8, and TNF-a; compare Table 3).
Iodination of VT-1 and the binding of nsl-VT-l to human mono­
cytes. VT-1 was radiolabeled with Nal2SI according to the lodogen 
procedure.27 The radioactive specific activity of l2SI-VT-l, as deter­
mined by self-displacement analysis,2” ranged from 3.3 to 10 p,Ci/ 
//g of protein.
After preincubation with or without LPS, the monocytes were
cooled to 4°C for 1 hour and gently kneaded, after which the mono­
cytes were obtained by needle aspiration with a 19-gauge needle. 
Subsequently the monocytes were washed twice in PBS/0.1 % bovine 
serum albumin (BSA) and transferred into tubes that were precoated 
with PBS/1 % BSA to avoid aspecific binding of the labeled toxin. 
The cells were incubated for 3 hours with 0.1 to 15 nmol/L l2SI-VT-
1 in PBS/1% BSA at 0°C. Cell-associated 12SI-VT-1 was determined 
after washing the cells for three times in excess of PBS/1% BSA. 
Aspecific binding was assessed in parallel incubation by determining 
the 125ï-VT-1 binding in the presence of a 75-fold excess of unlabeled 
VT-1. Cellular specific binding was calculated by subtracting the 
nonspecific binding determined in the presence of a 75-fold excess 
of unlabeled VT-1 from the cellular binding of ,25I-VT-1. All deter­
minations were done in duplicate. Data were analyzed using the 
method described by Seatchard.
To study the ability of the monoclonal antibody (MoAb) against 
the Gb, receptor to inhibit binding of l2SI-VT-l to human monocytes, 
the monocytes were incubated with the MoAb diluted into PBS/1% 
BSA 2 hours before and during the assay of l2:iI-VT~l binding.
Glycolipid extraction and TLC. Human monocytes cultured in 
teflon foil bags with and without LPS (1 ng/mL) for 36 hours were 
procured and washed twice with ice-cold PBS. Glycolipid,s were 
extracted as described by Lingwood et al2'': in short, the pellet was 
resuspended in PBS and 20 voi of chloroform/methanol (2:1, voi/ 
vol) were added. Cell debris was removed by performing filtration 
through glass-wool. One volume of water was added and partitioned. 
The lower phase was dried and incubated at 37°C for 2 hours in 0.4 
mol/L KOH in ethanol; 2 voi (vol/vol) o f chloroform was added 
and the mixture was partitioned against 2 voi of water. The lower 
phase was separated and frozen at —20°C until TLC-studies were 
performed.
For TLC the lower phase was dried and resuspended in chloro­
form/methanol (2:1, vol/vol). Samples were separated on a silica gel 
TLC plate using chloroform:methanol:water (65:25:4, vol/vol/vol). 
After separation the plate was soaked three times for 1 minute in 
0.01% polyisobutylmethacrylate in hexane and air dried, followed 
by overnight incubation in PBS/1 % BSA and 0.05% Tween 20. 
Subsequently, the plate was incubated with 50 mL, 1.5 nmol/L l25I- 
VT-1 in 1% BSA and 0.05% Tween-20 in PBS during 4 hours at 
4°C. The plate was washed extensively with PBS supplemented with 
1% BSA and 0.05% Tween-20, air dried and analyzed by a Fuji 
BAS 1000 phosphor-imager (Fuji, Leiden, The Netherlands).
Protein synthesis assay. Protein synthesis was determined by 
assaying the incorporation of •’H-lcucine (2.0 /¿Ci/mL) in 'H-proteins 
during an 8- to 48-hour incubation period with different concentra­
tions of VT-1. The incubation was followed by harvesting and wash­
ing with ice-cold PBS. Subsequently, cellular proteins as well as 
proteins present in the media were precipitated by adding ( 10% and 
20%, respectively) trichloroacetic acid. Precipitated proteins were 
dissolved in 0.3 mL 0.3 N NaOH; 60 /jL  1.5 N HCI was added and 
radioactivity was counted in a liquid scintillation counter.
Cytokine production. Human monocytes, cultured in teflon foil 
bags, were incubated with either LPS (range, 10 pg/mL to I ng/ 
mL) or VT- l (range, 1 nmol/L to 20 nmol/L) for 4, 12, 24, and 
36 hours. Unstimulated controls were exposed to medium alone. 
After the indicated periods of time the cells were procured and 
centrifuged. The supernatants were collected and stored at ~2()0C 
until assayed for the presence of cytokines. In additional experi­
ments, cycloheximide and polymyxin B were simultaneously 
added to confirm respectively necessity of protein synthesis and
/ of contamination with LPS, TNF-a as well as 11, - 1/) was 
assayed by radioimmunoassay.■',ul The sensitivity of bolh assays 
was 40 pg/mL. IL-6 was measured by an enzyme-linked immuno­
sorbent assay (ELISA) as described by Barrera et al'“; materials 
were a gift from Dr J. Wijdenes (Innotherapy, Besancon, France).
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Fig 1. Bacterial LPS increases the specific binding of 125I-VT-1 to 
nonadherent human monocytes. (A) Saturability of specific 125|-VT-1 
binding to human monocytes. Increasing concentrations (0*1 to 15 
nmol/L) of 125I-VT-1 were incubated for 3 hours at 4°C with 2 x 105 
human monocytes cultured in teflon foil bags either under basal con­
ditions (□) or after stimulation with LPS (0.1 /¿g/mL) for 36 hours
(■), Values are the mean ± SD of monocytes from three different 
donors. (B) The effect of LPS preincubation on the binding of 125I-VT- 
1 to human monocytes. Human monocytes were cultured in teflon
foil bags with (0.1 /xg/mL: T) and without LPS for various periods
of time (0 to 42 hours), after which the cells were obtained and 
counted* Subsequently the binding of 0.5 nmol/L 12tì[-VT-1 to 2 x 105 
human monocytes was assessed. Similar data were obtained with 
monocytes of a second donor. (C) Scatchard plot analysis of 12ÜI-VT* 
1 binding to human monocytes of one representative donor out of 
three. Cells were cultured in teflon foil bags either under basal condi­
tions (inset: O) or stimulated with LPS (0.1 /wg/mL: • )  for 36 hours. 
Inset: x-axis, B (mol/cell) x 10 10; y-axis, B/F (L/cell) x 10 10.
The »sensitivity of this ELISA w as 20 p g /m L . IL-8 was also deter- DNA amplification was performed with 2 //L of the RT reaction 
mined by an ELISA (R&D S ystem s Inc, Abingdon, UK), with a mixture in I x  polymerase chain reaction (PCR) buffer (20 mmol/ 
sensitivity of 18,1 pg/mL. L Tris-HCl pH 8,3, 50 mmol/L KCK 1.5 mmol/L MgC\I> 0.01%
gelatin) supplemented with 125 //mol/L dNTPs, 30 pmol each of 
5'- and 3' specific primers for IL*fvU| and /ï-actin (5' OCT ACCI
Detection ofmRNA. Human m onocytes (1 X  10’cells/mL) were 
cultured in teflon foil bags for 12 hours in the presence of either
to 280 nm.
control media or media supplemented with LPS (1 ng/mL) or VT- AGC TOC CTG ACGG 3' and 5' GAG GCC AGG ATG GAG
1 (10 nmol/L), After the indicated period o f  time the cells were CC 3') and 2.5 U of Taq polymerase (GIBCO-BRL) in a linai
obtained and pelleted by centrifugation at 2 0 0 g at 4°C. Cells were volume of 80 //L, All primers used for PCR were 50% CH C rich
subsequently washed twice with ice-cold P B S . Total cellular RNA and did not exhibit 3'-complementarity between primers pairs,
was extracted according to the R N A -zol B method .33 RNA amount Primers were designed to produce ampi icons spanning RNA-
and purity was assessed by measuring the optical densities at 260 splicing sites. The mixture was overlaid with 60 ¡jL  of mineral
oil. Initial dénaturation step consisted of 5 minutes at 94°C fol- 
cDNA34 was synthesized in 20  /¿L o f  reaction volumes con- lowed by amplification in 25 (/3-aetin) and 24, 26, 28, 30, and 32
(IL-6) segmental cycles at 94°C for 30 seconds, 56°C for 30 
seconds, and 72°C for 90 seconds (Perkin-Elmer Cetus instru­
ment; Norwalk, CT). All components used in cDNA synthesis 
L KC1, 3 mmol/L MgCL, and 2 0 0  U  o f  M o lo n e y  murine leukemia reaction and PCR were checked for possible contaminations (in 
virus reverse transcriptase (RT) (G IB C O -B R L , Life Technologies corresponding reactions lacking RNA or reverse transcriptase), 
bv, Breda, The Netherlands), A lter a 10-m inute incubation at Reaction products (20 fj.h) were analyzed by 1.5% agarose ( 1.5% 
20°C followed by a 45-minute incubation  at 42°C, samples were agarose, 0.01% ethidium bromide in Tris acetate/EDTA buffer)
4  <r 1  «  »  «  «  -
taining 0.5 /ig  o f m onocyte to ta l R N A , 5 /¿g /m L  of oligo (dT)12. 
in, 10 m m ol/L dithiothreitol, 0 .5  m m o l/L  d N T P s , 50 mmol/L Tris- 
HCl, pH 8.3, 20 U RNAsin (P ro m eg a , M a d iso n , WI), 75 mmol/
heated at 95°C for 10 minutes and then quick ly  chilled on ice. gel electrophoresis.
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Table 1. Binding of Verocytotoxin-1 (VT-1) to Human Monocytes
Cells Addition
Binding
Sites/Ceil
Apparent kd 
(nmol/L)
Donor 1 None 0.07 X 105 3.5
LPS (0.1 /Lüg/mL) 2.0 X 10s 2.3
Donor 2 None 0.08 X 10B 1.2
LPS (0,1 /¿g/mL) 1.8 X 10B 1.6
Donor 3 None 0.06 X 10B 3.3
LPS (0.1 /ig/mL) 1.8 X 105 1.0
Specific binding of 12ii-VT-1 (0.1 to 15 nmol/L) to human monocytes 
of three different donors using human monocytes cultured in teflon 
foil bags and exposed to either culture medium alone (controls) or 
supplemented with LPS (0.1 /jg/mL). The total number of specific 
binding sites and the apparent kd were calculated according to the 
method described by Scatchard.
RESULTS
LPS increases the number of VT-1 receptors on human 
monocytes. To determine the binding of l25I-VT-l to non­
adherent monocytes, monocytes that had been cultured and 
preincubated in teflon foil bags were used. The amount of 
specific ,25I-VT-i binding to these cells reached a maximum 
in 2 hours; it increased linearly with the cell concentration 
(not shown). The binding of 125I-VT-1 was saturable (Fig
1 A) and was entirely displaced by a 75-fold excess of unla­
beled VT-1. All further experiments were performed using
2 X 105 cells in a 100 /jL volume and a 3-hour incubation 
period with l35I-VT-l.
Preincubation of the cells with LPS caused a time-depen­
dent increase in VT-1 binding (Fig 1A and B). When the 
cells were cultured for 42 hours under basal conditions, no 
change in specific l25I-VT-l binding was observed (Fig IB). 
However, when the cells were incubated during the same 
time period with bacterial LPS an increase in specific l2sI~ 
VT-1 binding was observed, which became detectable after 
18 hours and progressed steadily for another 18 hours (Fig 
IB). The response was maximal with 1 ng/mL LPS and half- 
maximal with 0.1 ng/mL LPS (not shown). Scatchard plot 
analysis indicated that one type of binding site was involved 
(Fig 1C, Table 1). Furthermore, it showed that preincubation 
of monocytes with 0.1 //g/mL LPS for 36 hours caused a 
27-fold (range 23- to 30-fold) increase in the number of 
specific VT-1 binding sites, while the apparent affinity of 
l2i,I-VT-l did not change significantly (Table 1).
In addition to LPS, 36-hour preineubation of the cells with 
100 U/mL IL-2 and to a lesser extent with 33 ng/mL TNF- 
(X caused an increase in specific VT-l binding to 
(sixfold and twofold, respectively); 7 -interferon (150 
and IL-4 (300 U/mL) did not change this binding 
shown).
Characterization of the ligand to which VT-1 
monocytes. To investigate if globotriaosylceramide (Gb.0, 
which has been shown to be the receptor for VT-1 on endo­
thelial cells,3S lymphocytes,36 and in human kidney,'17 was 
also the receptor on monocytes, the cells were preincubated 
with LPS and an MoAb specifically recognizing Gb> The 
anti-Gb.i MoAb inhibited the binding of 12SI-VT-1 to stimu­
lated monocytes in a concentration-dependent way, although 
no complete inhibition was reached at the concentrations
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Fig 2. 125I-VT-1 binding to gíycolípíds extracted from human monocytes. Glycolipids were extracted from human monocytes cultured in 
teflon foil bags either under basal conditions or stimulated with LPS (1 ng/mL) during a 36-hour incubation period. Subsequently glycolipids 
were separated by TLC, assayed for 12BI-VT-1 binding, and visualized by phosphor-imager. Lanes A and B, glycolipid extracts of 10 x 10° human 
monocytes of one representative donor out of three; lane A, control human monocytes; lane B, LPS-stimulated human monocytes. Lanes C 
and D, glycolipid extracts of 1 x 106 human umbilical vein endothelial cells (HUVEC); lane C, LPS-stimulated cells; lane D, TNF^ (10 ng/mL)- 
treated cells. Lane E, standard neutral glycosphingolipids: 2 jug of each glycolipid. Lane F, orcinol staining of standard neutral glycosphingolipids 
(Gbl: galactosyiceramide; Gb2: lactosylceramide; Gb3: globotriaosylceramide; Gb4: globotetraosylceramide; Gb5; Forssman pentasaccharide). 
Lanes G and H, glycolipid extracts of 10 x 10° LPS-stimulated human monocytes; lane G, LPS-stimulated human monocytes; lane H, LPS- 
stimulated human monocytes supplemented with standard neutral glycosphingolipids Gb3).
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Fig 3. Effect of cycloheximide on the LPS-ïnduced increase în 12S1- 
VT-1 binding to human monocytes. Human monocytes were cultured 
in teflon foil bags either under basal conditions (■) or stimulated
with LPS (0.1 /ug/mL) for 36 hours (M). LPS-stimulated cells were 
simultaneously incubated with various concentrations of cyclohexi­
mide. Cells were obtained, washed, and counted, after which binding 
of 0,5 nmol/L 125|-VT-1 to 2 x 10s cells was determined. Shown are 
the data of monocytes of one representative donor out of two.
used (47% and 59% inhibition at 5% and 10% [vol/vol] 
antibody solution, respectively).
To further characterize the nature of the receptor for VT- 
1 present on human monocytes, neutral glycolipid extracts 
were prepared from both unstimulated and LPS-stimulated 
monocytes and TLC of these extracts was performed. After 
incubation of these thin-layer chromatograms with l25I-VT- 
1 and extensive washing, the bound 125I-VT-1 was detected 
by exposure to a phosphor-imager. The radiolabeled VT-1 
bound strongly to Gb3 and not to Gb4 when a standard prepa­
ration of neutral glycolipids was tested (Fig 2, lane E). In 
LPS- and TNF-a-stimulated human endothelial cells, VT- 
1 binding predominantly occurs to the classical Gbj (two 
bands probably related to differences in chain length of fatty 
acids) (Fig 2, lanes C and D). However, the basal and stimu­
lated VT-1 binding to monocyte glycolipids involves a neu­
tral glycolipid with an Rf value slightly higher than Gb,| (Fig 
2, lanes A and B). Because Gb4 does not bind VT-1, this 
may present other Gb3 forms, possibly Gba with short-chain 
fatty acids or a-OH-Gbj which both display a lower Rf value 
than the classical form of Gb.v This pattern was consistently 
found with different preparations of monocytes obtained 
from three different donors.
The increase in the binding of VT-l to the glycolipid 
extracts of LPS-stimulated monocytes (Fig 2, lanes A and 
B) indicates that the synthesis of VT-1 receptors is increased 
rather than the fact that it only reflects a redistribution of 
VT-1 receptors from intracellular stores toward the plasma 
membrane. In favor of an increased synthesis of proteins 
involved in Gb3 synthesis is the observation that the LPS- 
induced increase in VT-1 binding to monocytes was 
completely inhibi ted by the protein synthesis inhibitor cyclo­
heximide fFic 3). When LPS-stimulated monocvtes were
preincubated with cycloheximide only for 1 hour before har­
vesting, no change in VT-1 binding was found, excluding a 
direct effect of cycloheximide on the receptor availability or 
the binding assay itself.
Effect of VT-1 on protein synthesis and viability of mono­
cytes. To evaluate whether human monocytes, which pos­
sess a Gb3-like VT-1-receptor with a reduced Rf value, are 
sensitive to the toxic effect of VT-1, like other eukaryotic 
cells containing the classical Gb3,21 protein was
estimated from the incorporation of 1H-leucine in newly syn­
thesized proteins. No effect of VT-1 at concentrations rang­
ing from 1 to 10 nmol/L on protein synthesis by monocytes 
was observed over a 48-hour time period. Table 2 summa­
rizes the data on the effect of 24-hour incubation with 10 
nmol/L VT-1 or 1 ng/mL LPS on nonstimulated and LPS- 
stimulated monocytes obtained from three different donors. 
VT-1 exerted no effect on the overall protein synthesis by 
nonstimulated monocytes and LPS-stimulated monocytes of 
two donors, and had only a minor effect on protein synthesis 
in the LPS-stimulated cells of one donor (84% of control). 
No toxicity of 10 nmol/L VT-1 on nonstimulated and LPS- 
stimulated monocytes was observed, as determined by trypan 
blue exclusion test.
Effect of VT-1 on the production of cytokines by human 
monocytes. When human monocytes cultured in teflon 
bags were exposed to various concentrations of VT-1 for 
different periods of time, they started to produce consider­
able amounts of IL-1/3, IL-6, IL-8, and TNF-a (Fig 4; Table 
3). The time course of the production of these cytokines 
during incubation with 10 nmol/L VT-1 is given in Fig 4 
for monocytes of three different donors. The release of all 
four cytokines was enhanced after 4 hours and reached a 
maximum at 12 hours for TNF-a, whereas (dependently of 
the donor) the release of IL-1/3, IL-6, and IL-8 continued 
for 12 to 36 hours. The dose-response of cytokine release 
after 24 hours of incubation with VT-1 is shown in Fig 5. 
VT-1 concentrations of 1 to 20 nmol/L induced the release
Table 2. Effects of LPS and VT-1 on the Incorporation of 3H-Leucine
in 3H-Proteins by Human Monocytes
Cells Addition Control Preincubation With LPS
Donor 1 None 0.97 1.36
VT-1 (10 nmol/L) 1.05 1.39
LPS (1 ng/mL) 1.12 1.47
Don or 2 None 1.39 1.65
VT-1 (10 nmol/L) 1.59 1.38
LPS (1 ng/mL) 1.51 2.03
Donor 3 None 0.62 0.82
VT-1 (10 nmol/L) 0.81 0.92
LPS (1 ng/mL) 0.71 0.88
Control cells (control incubation) and LPS-stimulated cells (preincu­
bation with LPS (1 ng/mL for 36 hours) were cultured In teflon foil 
bags and exposed to control medium alone (None), control medium 
supplemented w ith VT-1 (10 nmol/L), or control medium supple­
mented with LPS (1 ng/mL) during a 24-hour Incubation period. Sub­
sequently, the incorporation of 3H-leucine into 3H-proteins was deter­
mined as described in Materials and Methods. Data are expressed as 
Incorporation of 3H-leucine Into 3H-proteins (pg/2 x 10® monocytes).
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Fig 4. Time kinetics of cyto­
kine release by human mono­
cytes induced by VT-1. Human 
monocytes of three different do­
nors were cultured in teflon foil 
bags (1.5 x l0°/3 mL) and incu­
bated with VT-1 (10 nmol/L) for 
various periods of time (0 to 36 
hours). At the indicated time 
points, conditioned media were 
collected and assayed for the cy­
tokines IL-1/3 (A), IL-6 (B), IL-8 (C), 
and TNF -tv (D) as described in 
Materials and Methods. Values 
from three different donors are 
given.
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of the indicated cytokines, a maximum being reached at 5 
to 10 nmol/L VT-1.
The effect of VT-1 was specific and was not caused by 
contamination in the VT-1 preparation. Heat-inactiva-1
tion (15 minutes at 90°C; two monocyte preparations of 
different donors) completely destroyed the ability of the VT- 
1 préparation (10 nmol/L) to induce the release of three
cytokines (IL-1/3, 1.9% ± 1.2%; IL-6, 6.1% ± 0.6%; TNF- 
a\ 4.5% ± 2.3% of control). Furthermore, addition of poly­
myxin B ( 1 /j.g/mL) did not reduce the effect of 10 nmol/L
,±; 34%), whereas it prevented the effect of 1VT-1
//g/ml. LPS on cytokine release (4.0%) ± 2.0%). Finally, 
preexposure of monocytes to LPS (I ng/mL; 36 hours) fol­
lowed by a second incubation with 1 ng/mL LPS caused
Table 3, The Cytokine-Inducing Effect of VT-1 and LPS
Cytokino
Dotermi nod Control
LPS 
(1 ng/mL)
VT-1 
(10 nmol/L)
IL-1// 
IL-6 
IL-8 
TNF-u
0.03 ± 0.03 
0.13 ± 0.09 
12.0 ± 8.5 
0.07 ± 0.01
10.3 ± 4.9
36.4 ± 3.7 
103 ± 61 
3.8 ± 1.7
3.9 ± 2.8 
20.3 ± 6.9 
99 ± 41 
2.2 ± 0.8
only a significant release of IL-1/3 after the first exposure 
to LPS. Nevertheless, the LPS-desensitized monocytes still 
respond to VT-I (Fig 6). In five experiments with two differ­
ent preparations of LPS-desensitized monocytes, IL-1/3 ac­
cumulation in the supernatant amounted to 111% ± 11% of 
control values after reincubation with 1 ng/mL LPS and 
247% ± 2 1% and 325% ± 101% after incubation with 1 
nmol/L VT-1 and 10 nmol/L VT-1, respectively (mean
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Human monocytes of throe different donors were cultured in teflon 
foil bags and exposed to either control medium alone or control me­
dium supplemented with either LPS (1 ng/mL) or VT-1 (10 nmol/L).
After 24 hours colls were obtained and conditioned media were col­
lected and assayed for the cytokines: IL-1/?, IL-6, IL-8, and TNF-a as conditioned media were collected and assayed for the cytokines IL- 
doscribed In Materials and Methods. Values are the mean (ng/mL) ±  %ß (A), IL-6 (A), TNF-a (A), and IL-8 (B). Shown are the data of human 
SD of monocytes of three different donors. monocytes of one representative donor out of three.
Fig 5. Dose-response of cytokine release by human monocytes 
induced by VT-1. Human monocytes (1.5 x 106/3 mL) were cultured 
in teflon foil bags and exposed to various concentrations of VT-1 (0 
nmol/L, □; 1 nmol/L, ■; 5 nmol/L, 0; 10 nmol/L, 0; and 20 nmol/ 
L, ■) during a 24-hour incubation period. Cells were procured and
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Fig 6. LPS-desensitized human monocytes do respond to VT-1. 
Human monocytes were cultured in teflon foil bags and stimulated 
with LPS (1 ng/mL) for 36 hours. Cells were obtained, washed, and 
counted. IL-1/J concentration in conditioned medium of the LPS-stim­
ulated monocytes was >  10 ng/mL. Subsequently, 2 x 106 LPS-stimu- 
lated cells were cultured in new teflon foil bags and either cultured 
in control medium (1) or control medium supplemented with VT-1 1 
nmol/L (2), VT-1 5 nmol/L (3), VT-1 10 nmol/L (4), or LPS (1 ng/mL) 
(5). After 6 0 ,1 2  (®), and 24 hours (£3) cells were obtained and
conditioned media were collected and assayed for IL-1/3.
SEM). The induction of the release of IL-1/3 by 10 nmol/L 
VT-1 was prevented by simultaneous addition of cyclohexi­
mide (2 iu,g/mL) (108% of control). This indicates that pro­
tein synthesis is required for the induction of this cytokine. 
To confirm the induction of the cytokine IL-6 at the mRNA
level, human monocytes were incubated with either culture 
medium or culture medium supplemented with 1 ng/mL LPS 
or 10 nmol/L VT-1. Total cellular RNA was extracted after 
a 12-hour incubation period and mRNA levels for IL-6 (Fig 
7) were determined by RT-PCR. To determine the linear 
range of amplification, the number of cycles ran for amplifi­
cation of IL-6 mRNA was varied (24, 26, 28, 30, and 32 
cycles). Figure 7 shows that only a weak band was observed 
in non-stimulated monocytes (lane 1) after 32 cycles, 
whereas marked increases in the IL-6 PCR signal become 
visible after 24 cycles in VT-1 (lane 2) and LPS-stimulated 
(lane 3) cells. The responses of VT-1 and LPS are rather 
similar. The housekeeping gene /3-actin was simultaneously 
amplified (25 cycles) in parallel tubes (Fig 7; left panel), 
indicating equivalent loading of the samples. Corresponding 
reactions lacking RNA or RT did not show any RT-PCR 
product. Specificity of the RT-PCR product (260 bp) was 
confirmed by restriction enzyme digestion.
DISCUSSION
Verocytotoxin producing E coli play an important role in 
the etiology of the epidemic form of HUS.2,38,39 In this study 
we have shown that freshly isolated human monocytes bind 
VT-1 to a Gbj species that is different from that found on 
endothelial cells and that the number of VT-1 binding sites 
is enhanced after incubation of the cells with LPS. Further­
more, we have demonstrated that instead of inhibiting protein 
synthesis, VT-1 specifically induces human monocytes to 
synthesize the cytokines IL-1/3, TNF-a, IL-6, and IL-8.
Several in vivo studies in humans and mice6,7,16'19'40,41 indi-
ß-ACTIN IL-6
25 24 26 28 30 32
587
298
174
Fig 7. IL-6 mRNA accumula­
tion in VT-1 and LPS-exposed 
human monocytes. Human 
monocytes cultured in teflon foil 
bags (10 x 106/10 mL) remained 
either untreated (controls) (1) or 
were incubated with VT-1 (10 
nmol/L) (2) or LPS (1 ng/mL) (3), 
After 12 hours of incubation the 
cells were procured and total cel­
lular RNA was extracted. mRNA 
was reverse transcripted and 
amplified in 25 (/?-actin) and 24, 
26, 28, 30, and 32 segmental 
cycles (IL-6). Specificity of the 
RT-PCR product (260 bp) was 
confirmed by restriction enzyme 
digestion (data not shown). A 
representative experiment of 
two identically performed exper­
iments is shown.
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cate that in addition to verocytotoxin, the sensitivity for LPS with a recent observation of Tesh et al,8 who reported that 
and the availability of the inflammatory mediator TNF-a mouse peritoneal macrophages express low to undetectable 
also play a role in the development and severity of the dis- amounts of Gb3 and that interaction of VT-1 with these
ease. Previous studies in vitro have shown that the sensitivity 
of endothelial cells for VT-1 markedly increases after 
exposure of cultured endothelial cells to TNF-a, IL-1, or
macrophages induces the production of IL-1, TNF-a, and IL- 
6. Our study and that by Tesh et al8 show that the induction of 
cytokine release is accompanied by an increase in cellular
LPS .')' 11’4“’43 Because monocytes and macrophages are able mRNA concentrations. In particular, our observation that
to produce and release these inflammatory mediators,20 we desensitisation of the monocytes for LPS prevented cytokine
investigated the interaction of human peripheral blood mono- release after a second LPS stimulation, while it did not re-
cytes with VT-1. Human monocytes express small amounts duce cytokine release by VT-1, strongly points to a stimula-
of VT-1 receptors, the number of which increased 23- to 30- 
fold after exposure of the cells to LPS due to an increase in 
receptor synthesis. This observation is of interest, because
tion of monocytes by VT-1 independently of LPS stimula­
tion. A similar conclusion was drawn by Tesh et al8 using 
mouse peritoneal macrophages from LPS-hyporesponsive
I-IUS is associated with a bloody diarrhea and plasma titers C3H/HeJ mice. Peritoneal macrophages from these LPS-
of antibodies against 0157 LPS were elevated in children hyporesponsive mice did respond in terms of cytokine re-
with HUS.44 Therefore, it is likely that part of the circulating lease when incubated with SLT-1 . The fact that in vivo these
monocytes become exposed to LPS.
The VT-1 receptor on monocytes appeared to be different 
from the classical Gb3 described for endothelial cells and 
lymphocytes.35,36 It interacts with MoAbs against Gb3, but
mice, which have a defective macrophage response after 
LPS challenge, showed a consistently longer mean time to 
death after inoculation with Shiga-like toxin II (VT-2), fur­
ther points to a cooperative effect between LPS and verocy-
has a relatively slow Rf value during TLC. The chromato- totoxins.6,40 Our data on the increase of VT-1 receptors on
graphic behavior is comparable with that of short-chain fatty
t  ^  »  V*
human monoCÿtes by LPS may be relevant in this context.
acyl Gb3 as described by Kiarash et al45 and also with that Firstly, because circulating VT-1 remain below detection
of a-OH-Gb3, which has been recognized by Jacewicz et 
al46 as a VT-1 binding receptor in erythrocyte membrane 
extracts. The exact nature of the receptor involved in VT-1 
binding to human monocytes remains to be clarified. Interest­
ingly, interaction of VT-1 with the receptor on monocytes 
did not affect the protein synthesis or viability of these cells, 
despite the fact that they express 2  X 105 receptors per 
cell after stimulation with LPS. Human umbilical endothelial 
cells expressing 10 X 105 receptors per cell were highly 
sensitive to VT-1. However, monocytes do respond to 
VT-1 by releasing cytokines. Therefore, it is likely that 
monocytes are less susceptible to the toxic effect of VT-1, 
although it cannot be excluded that the lower number of VT- 
1 receptors on monocytes partly contributes to the lack of 
sensitivity for VT-1 cytotoxicity. Alternatively, we cannot
level in blood plasma and the toxicity occurs predominantly 
in the kidney, monocytes may be involved in transporting 
the toxin from the intestine to the kidney. Secondly, once 
activated by LPS, monocytes increase their number of VT- 
1 receptors and probably respond more easily to the tiny 
concentrations of verocytotoxins that will be reached in 
HUS.
Our observation that VT-1 induces the release of inflam­
matory mediators also agrees with in vivo data of HUS 
patients showing elevated plasma concentrations of IL-8, IL- 
6, and TNF-a among HUS patients16'18 and elevated concen­
trations of TNF-a and IL-6 in urine of HUS patients.16,19 
Urinary concentrations being higher than serum concentra­
tions in individual patients points to a predominantly local 
role for inflammatory mediators. A local role was also sug-
exclude that the increase in VT-1 receptors is limited to a gested by Harel et al,7 who injected SLT-1 into transgenic
relatively small subpopulation of the monocytes. This may 
mask a toxic effect, because the majority of the cells are
mice bearing a chloramphenicol acetyltransferase (CAT) re­
porter gene coupled to a TNF-a promoter. After injection
nonresponsive. It remains to be investigated whether the lack of SLT-1 in these mice, CAT activity, reflecting stimulation
of toxicity by Gb3 with different fatty acyl moieties (Gb3 v 
short-chain fatty acyl Gb3 and a-OH-Gb3) is due to different 
localization and processing of these VT-1 receptors on the 
cell membrane. In this context it is of interest to note that 
different routes of internalization of Gb3 molecules have 
been reported, ie, via coated pits or via caveoli and transport 
to the Golgi region.47'40 A last possible explanation for hu-
of the TNF-a promoter, was induced in the kidney but not 
in other tissues.
The locally released cytokines, in particular TNF-a and 
IL-1/3, may increase leukocyte-endothelial cell interaction51 
and enhance the VT-1 receptors on endothelial cells and 
as such the sensitivity of these cells for the toxin.11 The 
accumulation of granulocytes in kidney biopsies of HUS
man monocytes not being susceptible to the toxic effect of patients has been well described as well as elevated concen-
VT-1 might be that regulation of ribosomal protein synthesis trations of IL-817 known to be chemotactic for granulocytes
in human monocytes reacts in a different way to VT-1 com- and elevated elastase levels indicating activation of granulo-
pared with that in endothelial cells. Such a different response cytes. However, the presence of monocytes in such biopsy
has been suggested to exist in Chinese hamster ovary (CHO) samples and the activation of monocytes remained unnoted.
Recently we have been able to analyze a biopsy sample taken
VT-I binding to human monocytes did not cause protein in the acute stage of a HUS patient. This biopsy specimen
synthesis inhibition, but it caused a considerable release of displayed a significant number of monocytes in the glomer-
the cytokines IL-1/3, TNF-a, IL-6, and IL-8 in a dose- and uli. This further underlies a possible involvement of blood
time-dependent manner. This observation closely agrees monocytes in the pathogenesis of HUS. Our observations
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that LPS increase the num ber o f  a  s p e c i f i c  type of VT-1 
receptors and that interaction o f  V T - 1  w ith  monocytes in­
duces the synthesis and re lea se  o f  v a r io u s  proinflammatory
cytokines m ay contribute to  u n d e r s ta n d in g  the complex cel­
lular interactions in H US.
16. Karpman D, Andreasson A, Thysell I I. Kaplan US, Svanborg
C: Cytokines in childhood hemolytic uremie syndrome mid throm­
botic thrombocytopenic purpura. Pediatr Nephrol 9:694, 1995
17. Fitzpatrick MM, Shah V, Trompeter RS, Dillon MJ, Barrati 
TM: Interleukin-8 and polymorphoneutrophil leucocyte activation 
in hemolytic uremic syndrome of childhood. Kidney Ini 42:951,
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